MX359110B - Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancer con un inhibidor de mek. - Google Patents
Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancer con un inhibidor de mek.Info
- Publication number
- MX359110B MX359110B MX2015004428A MX2015004428A MX359110B MX 359110 B MX359110 B MX 359110B MX 2015004428 A MX2015004428 A MX 2015004428A MX 2015004428 A MX2015004428 A MX 2015004428A MX 359110 B MX359110 B MX 359110B
- Authority
- MX
- Mexico
- Prior art keywords
- dihydro
- oxo
- combination
- mek inhibitor
- cancer activity
- Prior art date
Links
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title 1
- 229940124647 MEK inhibitor Drugs 0.000 title 1
- 230000001093 anti-cancer Effects 0.000 title 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- AHYMHWXQRWRBKT-UHFFFAOYSA-N tepotinib Chemical compound C1CN(C)CCC1COC1=CN=C(C=2C=C(CN3C(C=CC(=N3)C=3C=C(C=CC=3)C#N)=O)C=CC=2)N=C1 AHYMHWXQRWRBKT-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
Abstract
Una composición farmacéutica que comprende 3-(1-{3-[5-(1-metil-pip eridin-4-ilmetoxi)-pirimidin-2-il]-bencil}-6-oxo-1,6-dihidro-piri dazin-3-il)-benzonitrilo o una de sus sales y/o solvatos farmacéuticamente aceptables y N-((S)-2,3-dihidroxi-propil)-3-(2-f luoro-4-yodo-fenilamino)- isonicotinamida o una de sus sales y/o solvatos farmacéuticamente aceptables.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12007039 | 2012-10-11 | ||
| PCT/EP2013/002747 WO2014056566A1 (en) | 2012-10-11 | 2013-09-13 | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a mek inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015004428A MX2015004428A (es) | 2015-06-24 |
| MX359110B true MX359110B (es) | 2018-09-14 |
Family
ID=47048932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015004428A MX359110B (es) | 2012-10-11 | 2013-09-13 | Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancer con un inhibidor de mek. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20150297594A1 (es) |
| EP (1) | EP2906294B1 (es) |
| JP (1) | JP2015536910A (es) |
| KR (1) | KR102157501B1 (es) |
| CN (1) | CN104703655A (es) |
| AR (1) | AR092991A1 (es) |
| AU (1) | AU2013329865B2 (es) |
| BR (1) | BR112015007870B1 (es) |
| CA (1) | CA2887628C (es) |
| ES (1) | ES2679372T3 (es) |
| HK (1) | HK1211255A1 (es) |
| IL (1) | IL238061B (es) |
| MX (1) | MX359110B (es) |
| RU (1) | RU2684407C2 (es) |
| SG (1) | SG11201502628SA (es) |
| WO (1) | WO2014056566A1 (es) |
| ZA (1) | ZA201503186B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170090498A (ko) * | 2014-12-11 | 2017-08-07 | 메르크 파텐트 게엠베하 | 항암 활성을 갖는 6-옥소-1,6-디히드로-피리다진 유도체와 퀴나졸린 유도체의 조합 |
| RU2017124612A (ru) * | 2014-12-12 | 2019-01-14 | Мерк Патент Гмбх | Комбинация производного 6-оксо-1, 6-дигидро-пиридазона, обладающего противораковой активностью, с ингибитором рэфр |
| RS61126B1 (sr) * | 2016-10-27 | 2020-12-31 | Fujian Cosunter Pharmaceutical Co Ltd | Jedinjenje piridona kao inhibitor c-met |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007032507A1 (de) * | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| CN101653607B (zh) * | 2008-08-19 | 2013-02-13 | 鼎泓国际投资（香港）有限公司 | 含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途 |
| AR084216A1 (es) * | 2010-12-09 | 2013-05-02 | Sanofi Sa | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit |
-
2013
- 2013-09-13 CN CN201380053015.8A patent/CN104703655A/zh active Pending
- 2013-09-13 AU AU2013329865A patent/AU2013329865B2/en active Active
- 2013-09-13 CA CA2887628A patent/CA2887628C/en active Active
- 2013-09-13 SG SG11201502628SA patent/SG11201502628SA/en unknown
- 2013-09-13 MX MX2015004428A patent/MX359110B/es active IP Right Grant
- 2013-09-13 RU RU2015117550A patent/RU2684407C2/ru active
- 2013-09-13 US US14/434,926 patent/US20150297594A1/en not_active Abandoned
- 2013-09-13 WO PCT/EP2013/002747 patent/WO2014056566A1/en active Application Filing
- 2013-09-13 BR BR112015007870-2A patent/BR112015007870B1/pt active IP Right Grant
- 2013-09-13 EP EP13762992.9A patent/EP2906294B1/en active Active
- 2013-09-13 KR KR1020157012085A patent/KR102157501B1/ko active IP Right Grant
- 2013-09-13 JP JP2015536004A patent/JP2015536910A/ja active Pending
- 2013-09-13 ES ES13762992.9T patent/ES2679372T3/es active Active
- 2013-10-11 AR ARP130103703A patent/AR092991A1/es unknown
-
2015
- 2015-03-31 IL IL23806115A patent/IL238061B/en active IP Right Grant
- 2015-05-08 ZA ZA2015/03186A patent/ZA201503186B/en unknown
- 2015-12-07 HK HK15112009.7A patent/HK1211255A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2887628A1 (en) | 2014-04-17 |
| ES2679372T3 (es) | 2018-08-24 |
| US20150297594A1 (en) | 2015-10-22 |
| EP2906294A1 (en) | 2015-08-19 |
| CN104703655A (zh) | 2015-06-10 |
| RU2684407C2 (ru) | 2019-04-09 |
| EP2906294B1 (en) | 2018-04-18 |
| AR092991A1 (es) | 2015-05-13 |
| JP2015536910A (ja) | 2015-12-24 |
| AU2013329865A1 (en) | 2015-05-21 |
| ZA201503186B (en) | 2021-09-29 |
| WO2014056566A1 (en) | 2014-04-17 |
| CA2887628C (en) | 2020-09-08 |
| IL238061B (en) | 2019-10-31 |
| IL238061A0 (en) | 2015-05-31 |
| KR20150067343A (ko) | 2015-06-17 |
| SG11201502628SA (en) | 2015-05-28 |
| BR112015007870A2 (pt) | 2017-07-04 |
| AU2013329865B2 (en) | 2018-04-26 |
| MX2015004428A (es) | 2015-06-24 |
| RU2015117550A (ru) | 2016-12-10 |
| KR102157501B1 (ko) | 2020-09-18 |
| HK1211255A1 (en) | 2016-05-20 |
| BR112015007870B1 (pt) | 2021-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35998A (es) | 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA | |
| EA201070598A1 (ru) | Терапевтическое применение соединений, обладающих комбинированной активностью в отношении sert, 5-htи 5-ht | |
| RS54608B1 (en) | CGRP RECEPTOR ANTAGONITY | |
| DK2373640T3 (da) | Hidtil ukendte polymorfe former af 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitril-hydrochloridsalt og fremgangsmåder til fremstilling deraf | |
| MX2016003754A (es) | Una composicion farmaceutica estable que contiene amlodipina y valsartan. | |
| JP2012136529A5 (es) | ||
| MX359110B (es) | Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancer con un inhibidor de mek. | |
| PH12017502252A1 (en) | Stable pharmaceutical composition for oral administration | |
| PH12017500719A1 (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative | |
| PH12017500718A1 (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor | |
| MX343273B (es) | Intermediarios clave para la sintesis de rosuvastatina o de sales farmaceuticamente aceptables de la misma. | |
| PH12017501832A1 (en) | Stabilized pharmaceutical composition | |
| PH12016500948A1 (en) | Combination of a 6-oxo- 1,6-dihydro-pyridazine derivate having anti-cancer activity with gefitinib | |
| MX349724B (es) | Usos terapeuticos de 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperaz ina. | |
| EA201001125A1 (ru) | Фармацевтические композиции, включающие n-[2-(диэтиламино)этил]-5-[(5-фтор-1,2-дигидро-2-оксо-3н-индол-3-илиден)метил]-2,4-диметил-1н-пиррол-3-карбоксамид | |
| HRP20171295T1 (hr) | Derivat 6-okso-1,6-dihidro-piridazina za upotrebu za liječenje hepatocelularnog karcinoma (hcc) | |
| MX2017001869A (es) | Formas cristalinas de un modulador de receptor de estrogeno. | |
| BR112017012558A2 (pt) | Composições de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h- indazol-5-il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il) fenil)-3,6-diidropiridin-1(2h)-il)-2-oxoetil)-3-(metiltio) pirrolidina-3-carboxamida para preparações farmacêuticas | |
| PH12016500964A1 (en) | A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (rcc) | |
| EA201391348A1 (ru) | КОМБИНАЦИИ АКТИВАТОРОВ АЛЬФА-7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И АНТАГОНИСТОВ mGluR5, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ ПРИ ВЫЗВАННОЙ ДОПАМИНОМ ДИСКИНЕЗИИ, СВЯЗАННОЙ С БОЛЕЗНЬЮ ПАРКИНСОНА | |
| MY183976A (en) | Pharmaceutical composition for oral administration with improved dissolution and/or absorption | |
| BR112022000266A2 (pt) | Preparação farmacêutica | |
| MX2017008497A (es) | Nuevos compuestos heterocíclicos y su uso tanto en medicina como en cosmética. | |
| UA88008U (en) | 3-(phenoxymethyl)-5-(propylthio)-1h-1,2,4-triazole exhibiting actoprotector activity | |
| EA201101328A1 (ru) | Соединение для лечения туберкулеза |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |